Da Volterra's DAV132 Shown As Promising Candidate for Preventing Severe C. Difficile Infections

Product News   May 13, 2014

 
Da Volterra's DAV132 Shown As Promising Candidate for Preventing Severe C. Difficile Infections
 
 
FURTHER INFORMATION
 
 
 

Related Product News

QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Lung Cancer

Product News

Extended labeling claim adds detection of three additional gene mutations to provide the most comprehensive mutation panel for GILOTRIF®

READ MORE

Gyros Protein Technologies Introduces Multi-Species Kit for Toxicokinetic Studies

Product News

Gyrolab Generic TK Kit for early-stage biotherapeutic development, optimized for use in Gyrolab systems.

READ MORE

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology

Product News

Lightning-Link is now available in volumes from 10µg to 100mg. Direct-labeling technology provides excellent batch-to-batch consistency and high performance.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE